Vitality Biopharma Inc (OTCMKTS:VBIO) uses its proprietary cannaboside prodrug, which enables it to deliver a specific and targeted dose of its CBD compound. In prior, non-related trials, cannabinoids have shown the ability to effectively cure Crohn’s disease patients, with more than 40% of the subjects having had the ailment put into remission. These previous results, though unconnected to company, do have the prospect to open added regulatory pathways for accelerated nod, with both 505(b)1 and 505(b)2 filings possibly available to company.
The highlights
Vitality Biopharma has shown itself to be a radical presence in the CP segment, advancing a new series of cannaboside prodrugs that can offer a potent site-specific technique of delivery to offer local therapeutic impact, while at the same time eliminating or reducing the systemic delivery into the brain and bloodstream of THC, the compound within the crop that leads in a psychoactive response.
Using the stimulated power of the prodrug, the firm is in the unique position of offering patients with a tremendously potent dosage of the active cannabosides that bring the response. It is a remarkable differentiating factor for company, because as others may possibly be advancing through clinical and pre-clinical studies, the amount of CBD that can be utilized by them is considerably mitigated due to the effects of the surplus THC that is transmitted to the brain. It makes the VBIO prodrug a remarkably important component of the firm’s clinical studies, and shows more promise than its peers in getting a product rapidly to market.
Vitality Biopharma’s stable of unique cannabinoid prodrugs has demonstrated reliable improvements in both drug stability and solubility within the cannabosides. These improvements have led to over 20 patent pending CBD compounds that will strengthen the VBIO intellectual asset portfolio, and will also offer additional revenue making resources for company.
While the prodrug know-how itself is not a new idea, VBIO’s innovative compositions of matter, comprising its glycoside prodrugs of CBD, CBDV and THC associated compounds are, and each may assist to get an enormous competitive benefit, particularly with the prospective that each compound may relish patent protection over the year 2035.
